I’d buy this Covid-19-related penny stock

This penny stock is developing a Covid-19 vaccine that could build long-term immunity and treat the variants of the virus.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve recently come across the penny stock Scancell (LSE: SCLP) and I believe it has lots of potential. But would I buy? Here’s my take on the company.

Scancell: an overview

In a nutshell, Scancell is an immuno-oncology  company. That’s a fancy way of saying it develops treatments that stimulate the body’s own immune system to treat or prevent cancer.

Scancell isn’t just a company with an idea. It has four types of scientific technology. These include: ImmunoBody, Moditope, AvidiMab and COVIDITY. It’s very early days for the firm, but some of its products are undergoing clinical trials.

Scancell’s lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. That’s skin cancer that has spread to other parts of the body. SCIB 1 has completed Phase 1 trials and will be moving to Phase 2.

I think things look promising for Scancell and would buy the penny stock today.

Coronavirus

While treating and preventing certain types of cancer is Scancell’s bread and butter, I think the real star of the show is its COVIDITY programme.

In April 2020, the company decided to initiate a research programme called, COVIDITY to develop a vaccine for Covid-19. It’s being worked on with scientists at the University of Nottingham.

What I like about Scancell’s version of a vaccine is that it’s intended to be a second-generation jab. That means it could be effective against many of the coronavirus variants. It comes after concerns that the Pfizer and AstraZeneca vaccines may offer limited protection against the mutated versions of the virus.

The science bit

I’ll try and explain the science part.

Most of the current vaccines target the surface spike (S) protein, which allows the virus to infect the cell. Scancell’s vaccine not only targets the S protein but also the nucleocapsid (N) protein, which makes the bulk of the virus particle.

Scancell says that the N-protein is “highly conserved”, which means it’s less likely to mutate. In summary, the fact that Scancell is targeting the N-protein means that it could create long-term immunity against the coronavirus and its variants.

Do we need another vaccine?

I think another Covid-19 vaccine is important. Given the concerns about currently available vaccines, I feel there is always room for improvement. Especially around effectiveness, safety and longevity of response of a vaccine. 

I also like that Scancell’s version is relatively simple to manufacture and doesn’t need to be stored in ultra-low temperatures. This means transportation is likely to be easier.

The risks

Big pharma companies with a lot more resources are also working on jabs to treat coronavirus variants. Scancell is at an early stage and there’s no guarantee its treatments will be successful in testing trials. It’s a pre-revenue, loss-making company. Research and development costs are likely to persist and hit profitability. This penny stock is not for the faint hearted. So I’d only buy what I could afford to lose.

While Scancell has raised the necessary funding to trials its products, any delays or setbacks may require the company to raise additional funds. This could also impact the share price.

But as a long-term investor, I feel the potential rewards outweigh these risks and I’d buy the penny stock in my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »